BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2653 related articles for article (PubMed ID: 18360113)

  • 1. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
    Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
    Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent mitotic activity in banal melanocytic nevi uncovered by immunohistochemical analysis.
    Glatz K; Hartmann C; Antic M; Kutzner H
    Am J Dermatopathol; 2010 Oct; 32(7):643-9. PubMed ID: 20661119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
    Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
    Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions.
    Li LX; Crotty KA; McCarthy SW; Palmer AA; Kril JJ
    Am J Dermatopathol; 2000 Dec; 22(6):489-95. PubMed ID: 11190439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions.
    Vetter CS; Müller-Blech K; Schrama D; Bröcker EB; Becker JC
    Arch Dermatol Res; 2005 Jul; 297(1):26-30. PubMed ID: 15906050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
    Isabel Zhu Y; Fitzpatrick JE
    J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical studies of conjunctival nevi and melanomas.
    Jakobiec FA; Bhat P; Colby KA
    Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fascin expression in melanocytic lesions of the skin.
    YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
    Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma.
    Abdou AG; Hammam MA; Farargy SE; Farag AG; El Shafey EN; Farouk S; Elnaidany NF
    Am J Dermatopathol; 2010 Dec; 32(8):809-14. PubMed ID: 20885286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic skin lesions.
    Gambichler T; Shtern M; Rotterdam S; Bechara FG; Stücker M; Altmeyer P; Kreuter A
    J Am Acad Dermatol; 2009 May; 60(5):808-13. PubMed ID: 19389522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Unusual and unknown aspect of cutaneous malignant melanoma: minimal deviation malignant melanoma. Retrospective study of 45 cases].
    Mérot Y; Mihm MC
    Ann Dermatol Venereol; 1985; 112(4):325-36. PubMed ID: 4026131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
    Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
    J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
    Lampert A; Thomine E; Lauret P; Hemet J
    Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fascin, cortactin and survivin expression of melanocytic neoplasms and association with clinicopathological parameters and anatomic locations in Chinese people.
    Gao HW; Yu CP; Lee HS; Nieh S; Chiang CP; Wang WM; Jin JS
    Eur J Dermatol; 2010; 20(3):293-301. PubMed ID: 20400386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pigmented spindle cell nevus: clues for differentiating it from spindle cell malignant melanoma. A comprehensive survey including clinicopathologic, immunohistochemical, and FISH studies.
    Díaz A; Valera A; Carrera C; Hakim S; Aguilera P; García A; Palou J; Puig S; Malvehy J; Alos L
    Am J Surg Pathol; 2011 Nov; 35(11):1733-42. PubMed ID: 21997694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 133.